Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Biologic agents added to non-surgical periodontal therapy for intrabony defects

Official title: Evaluation of the Efficacy of rhPDGF, L-PRF and EMD as an Adjunct to Non-surgical Periodontal Therapy of Intrabony Defects: a Randomized Controlled Clinical Trial

Run by G. d'Annunzio University · NCT05858411 · Data updated 2026-11-12

This study tests whether adding rhPDGF, L-PRF, or enamel matrix derivatives to minimally invasive non-surgical therapy helps restore deep bone defects in periodontitis patients.

More Periodontal Diseases trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment88 (estimated)
SponsorG. d'Annunzio University
Academic / other
Locations1 site (Tirana)
StatusRecruiting
StartedJanuary 8, 2023
Main results expectedSeptember 1, 2027
Study endsSeptember 1, 2027
Registry record updatedMay 28, 2026
Trial IDNCT05858411 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with stage III–IV periodontitis, non-smokers or former smokers quit for at least 1 year, with at least one infrabony defect (PPD ≥ 5 mm, defect depth ≥ 3 mm) and no recent periodontal treatment.

Probably not a fit

Patients with three-wall infrabony defects, uncontrolled systemic conditions, recent antibiotic therapy, or ongoing orthodontic treatment may not see additional benefits.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized clinical trial will compare four treatment approaches over 12 months in patients with infrabony defects due to periodontitis. Participants will be allocated to MINST alone, MINST with rhPDGF, MINST with L-PRF, or MINST with enamel matrix derivatives, with each defect treated under local anesthesia using ultrasonic and hand instrumentation. Outcomes will be assessed clinically and radiographically to determine relative effectiveness in attachment gain and defect fill. The study aims to determine if adding biologic or regenerative agents to MINST provides additional benefits over MINST alone.

Why it matters

Potential benefit: If successful, patients could experience greater pocket depth reduction and attachment gain with certain biologic adjuncts to MINST.

How similar studies have gone: Prior regenerative approaches in periodontal defects have shown variable improvements; this study tests multiple adjuncts against MINST alone to identify potential advantages.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with a diagnosis of periodontitis stage III or IV (grades A to C),
* non-smokers or former smokers who quit at least 1 year ago, and
* had not received any periodontal treatment in the 3 months prior to recruitment;
* Presence of at least 1 Infrabony defect (PPD ≥ 5 mm with infrabony defect depth of ≥3mm at screening radiograph);
* One and two wall infrabony defects at screening radiograph and periodontal charting.
* Signed informed consent.

Exclusion Criteria:

* Presence of uncontrolled systemic diseases that could affect treatment outcomes such as diabetes mellitus with an HbA1C\>7%, rheumatoid arthritis or any form of immunosuppression;
* Subjects requiring antibiotic prophylaxis;
* 3-wall infrabony defects;
* Patients that had received systemic or local delivery of antibiotic therapy 6 weeks before enrollment;
* Presence of furcation defect;
* Chronic intake of NSAIDs or steroids, currently;
* Patients undergoing orthodontic treatment, having removable prosthetic appliances, pregnancy, tumors of the oral cavity or the presence of any psychiatric condition that could affect participation.

Where it's running

  • University of Medicine of Tirana
    Tirana, Albania
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.